Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine

Drug Metabolism and Pharmacokinetics

Volumn 29, Issue 2, 2014, Pages 120-128

  Son, Hankil ^a,b   Lee, Donghwan ^a,b   Lim, Lay Ahyoung ^a,b   Jang, Seong Bok ^c   Roh, Hyerang ^a,b   Park, Kyungsoo ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yuhan Corporation   (South Korea)

Author keywords

Amlodipine; Drug drug interaction; Metabolite; Population anlyisis; Simvastatin; Vmixture model

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MEVINOLIN; SIMVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENTIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; KOREAN (PEOPLE); MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; ADULT; AGE; BIOAVAILABILITY; BIOLOGICAL MODEL; BLOOD; BODY WEIGHT; DRUG INTERACTION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHENOTYPE; POLYPHARMACY; SOUTH KOREA;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AMLODIPINE; BIOLOGICAL AVAILABILITY; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; GENOTYPE; HEALTHY VOLUNTEERS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PHENOTYPE; POLYMORPHISM, GENETIC; POLYPHARMACY; REPUBLIC OF KOREA; SIMVASTATIN;

EID: 84901229599     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-13-RG-053     Document Type: Article

References (20)

1. Grasela, T. H., Jr., Antal, E. J., Ereshefsky, L., Wells, B. G., Evans, R. L. and Smith, R. B.: An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin. Pharmacol. Ther., 42: 433-441 (1987).
2. Berg, J. M., Tymoczko, J. L. and Stryer, L.: Biochemistry. 5th ed. New York, W. H. Freeman, 2002.
3. Pedersen, T. R. and Tobert, J. A.: Simvastatin: a review. Expert Opin. Pharmacother., 5: 2583-2596 (2004).
4. Kim, K. A., Park, P. W., Lee, O. J., Kang, D. K. and Park, J. Y.: Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J. Clin. Pharmacol., 47: 87-93 (2007).
5. Murdoch, D. and Heel, R. C.: Amlodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease. Drugs, 41: 478-505 (1991).
6. Thacker, H. P.: S-amlodipine-the 2007 clinical review. J. Indian Med. Assoc., 105: 180-182, 184, 186 passim (2007).
7. Kim, K. A., Park, P. W., Lee, O. J., Choi, S. H., Min, B. H., Shin, K. H., Chun, B. G., Shin, J. G. and Park, J. Y.: Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin. Pharmacol. Ther., 80: 646-656 (2006).
8. Nishio, S., Watanabe, H., Kosuge, K., Uchida, S., Hayashi, H. and Ohashi, K.: Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens. Res., 28: 223-227 (2005).
9. Jemal, M., Ouyang, Z. and Powell, M. L.: Direct-injection LC-MS-MS method for high-throughput simultaneous quantitation of simvastatin and simvastatin acid in human plasma. J. Pharm. Biomed. Anal., 23: 323-340 (2000).
10. Zhang, N., Yang, A., Rogers, J. D. and Zhao, J. J.: Quantitative analysis of simvastatin and its beta-hydroxy acid in human plasma using automated liquid-liquid extraction based on 96-well plate format and liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal., 34: 175-187 (2004).
11. Ma, Y., Qin, F., Sun, X., Lu, X. and Li, F.: Determination and pharmacokinetic study of amlodipine in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry. J. Pharm. Biomed. Anal., 43: 1540-1545 (2007).
12. Suchanova, B., Kostiainen, R. and Ketola, R. A.: Characterization of the in vitro metabolic profile of amlodipine in rat using liquid chromatography-mass spectrometry. Eur. J. Pharm. Sci., 33: 91-99 (2008).
13. Boeckmann, A. J., Sheiner, L. B. and Beal, S. L.: NONMEM User's Guide. Ellicott City, Icon Development Solutions, 2011.
14. Lindbom, L., Ribbing, J. and Jonsson, E. N.: Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming. Comput. Methods Programs Biomed., 75: 85-94 (2004).
15. Jonsson, E. N. and Karlsson, M. O.: Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed., 58: 51-64 (1999).
16. Savic, R. M., Jonker, D. M., Kerbusch, T. and Karlsson, M. O.: Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn., 34: 711-726 (2007).
17. Ette, E. I. and Williams, P. J.: Pharmacometrics: The science of quantitative pharmacology, Hoboken, John Wiley & Sons, Inc., 2007.
18. Thummel, K. E.: Gut instincts: CYP3A4 and intestinal drug metabolism. J. Clin. Invest., 117: 3173-3176 (2007).
19. Park, C. G., Lee, H., Choi, J. W., Lee, S. J., Kim, S. H. and Lim, H. E.: Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int. J. Clin. Pharmacol. Ther., 48: 497-503 (2010).
20. Cotreau, M. M., von Moltke, L. L. and Greenblatt, D. J.: The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin. Pharmacokinet., 44: 33-60 (2005).